Pegvisomant Disease Interactions
There are 2 disease interactions with pegvisomant.
Pegvisomant (applies to pegvisomant) diabetes
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
Pegvisomant is an analog of human growth hormone (GH) that selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. The use of growth hormones opposes the effects of insulin on carbohydrate metabolism by decreasing insulin sensitivity; therefore, glucose intolerance may improve in some patients treated with pegvisomant. Diabetic patients should be monitored closely, and the doses of anti-diabetic drugs may be reduced as necessary to avoid hypoglycemia. Blood glucose levels should be evaluated as appropriate.
Pegvisomant (applies to pegvisomant) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in patients treated with pegvisomant. Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with pegvisomant. Care should be exercised when using this agent in patients with liver dysfunction and its use should be used in accordance with the information presented in the manufacturer prescribing information with respect to liver test abnormalities.
Switch to professional interaction data
Pegvisomant drug interactions
There are 74 drug interactions with pegvisomant.
More about pegvisomant
- pegvisomant consumer information
- Check interactions
- Compare alternatives
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: growth hormone receptor blockers
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Sandostatin
Sandostatin is used to treat acromegaly and to reduce flushing episodes and watery diarrhea caused ...
Sandostatin LAR Depot
Sandostatin LAR Depot is used for acromegaly, carcinoid tumor, vasoactive intestinal peptide tumor
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Parlodel
Parlodel is used for acromegaly, hyperprolactinemia, parkinson's disease
Cycloset
Cycloset is used to treat Type 2 Diabetes. Learn about side effects, interactions and indications.
Somatuline Depot
Somatuline Depot is used as a long-term treatment for acromegaly. Learn about side effects ...
Signifor
Signifor (pasireotide) is a man-made protein that is similar to somatostatin and is used to treat ...
Mycapssa
Mycapssa (octreotide) is used for the treatment of acromegaly. Includes Mycapssa side effects ...
Bromocriptine
Bromocriptine is used for acromegaly, hyperprolactinemia, parkinson's disease, tardive dyskinesia ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.